Skip to main content
Elsevier

Anti-Prostate Cancer Agents

  • 1st Edition - May 23, 2025
  • Latest edition
  • Author: Qiao-Hong Chen
  • Language: English

Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book… Read more

Description

Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book covers discovery/design, synthetic studies, preclinical evaluation, mechanism of action, structure-activity relationships, clinical studies/applications of anti-prostate cancer agents.

This book provides insight on how the design and discovery process of anti-prostate cancer agents have evolved from androgen deprivation therapy to current androgen receptor antagonists/degraders. So far, no book focusing on the topic has been published.

Key features

  • Provides insight on how the design and discovery process of anti-prostate cancer agents have evolved
  • Explore the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications
  • Highlight the molecular targets and mechanism of action for anti-prostate cancer agents

Readership

Graduate students and researchers working on drug discovery and development, Medicinal Chemistry, Bioorganic Chemistry, Chemical Biology, and Biomedical Science

Table of contents

1. Introduction: Overview of Prostate Cancer     

2. Why has one got prostate cancer?

3. Androgen Deprivation Therapy

4. Anti-prostate cancer agents interacting with topoisomerase

5. Microtubule-Stabilizing Compounds as Anti-Prostate Cancer Agents

6. Androgen/Androgen Receptor Signaling Pathway and Prostate Cancer 

7. Anti-Prostate Cancer Agents Suppressing Androgen Biosynthesis 

8. First Generation Nonsteroidal Androgen Receptor Antagonists 

9. Second Generation Nonsteroidal Androgen Receptor Antagonists

10. Anti-Prostate Cancer Agents Interacting with N-Terminal Domain of Androgen Receptor

11. Androgen Receptor Degraders as Anti-Prostate Cancer Agents

12. Radiotherapeutics for treatment of Prostate Cancer

13. Immunotherapy for Prostate Cancer

14. Radiosensitizer for prostate cancer 

15. Anti-Prostate Cancer Agents Targeting Prostate-Specific Membrane Antigen

16. Anti-Prostate Cancer Agents Targeting Poly(ADP-Ribose)Polymerase

17. Combined Anti-Prostate Cancer Agents

18. Future Directions

Product details

  • Edition: 1
  • Latest edition
  • Published: July 25, 2025
  • Language: English

About the author

QC

Qiao-Hong Chen

Dr. Qiao-Hong Chen is a Professor in the Department of Chemistry & Biochemistry at California State University, Fresno. She received her Ph.D. in Medicinal Chemistry from Sichuan University, China, and completed postdoctoral and senior research training at the University of Alberta, Canada, and Virginia Tech, USA. Her research and teaching span medicinal chemistry, organic synthesis, natural products, anticancer agents, and drug discovery, with particular expertise in prostate cancer therapeutics and androgen receptor-related strategies. Dr. Chen has published 168 peer-reviewed articles and authored the book titled Anti-Prostate Cancer Agents, published by Elsevier in 2025. She has also author or co-authored five additional books and book chapters in medicinal chemistry, natural products, and anticancer drug discovery. Dr. Chen has served as a Visiting Research Scholar at Princeton University and as a guest editor for three Special Issues on “Anticancer Agents: Design, Synthesis and Evaluation” of Molecules.
Affiliations and expertise
Professor and Graduate Coordinator, Department of Chemistry and Biochemistry, California State University, California, USA

View book on ScienceDirect

Read Anti-Prostate Cancer Agents on ScienceDirect